Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Karyopharm Therapeutics Inc. | Financial_Report.xls |
| EX-31.1 - EX-31.1 - Karyopharm Therapeutics Inc. | d824483dex311.htm |
| EX-32.1 - EX-32.1 - Karyopharm Therapeutics Inc. | d824483dex321.htm |
| EX-31.2 - EX-31.2 - Karyopharm Therapeutics Inc. | d824483dex312.htm |
| EX-23.1 - EX- 23.1 - Karyopharm Therapeutics Inc. | d824483dex231.htm |
| EX-21.1 - EX-21.1 - Karyopharm Therapeutics Inc. | d824483dex211.htm |
| EX-10.16 - EX-10.16 - Karyopharm Therapeutics Inc. | d824483dex1016.htm |
| EX-10.21 - EX-10.21 - Karyopharm Therapeutics Inc. | d824483dex1021.htm |
| EX-10.17 - EX-10.17 - Karyopharm Therapeutics Inc. | d824483dex1017.htm |
| EX-10.22 - EX-10.22 - Karyopharm Therapeutics Inc. | d824483dex1022.htm |
| 10-K - 10-K - Karyopharm Therapeutics Inc. | d824483d10k.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement (No. 333-194746) on Form S-8 and Registration Statement (No. 333-201366) on Form S-3 of Karyopharm Therapeutics Inc. of our report dated March 21, 2014, relating to our audit of the consolidated financial statements, which appear in this Annual Report on Form 10-K of Karyopharm Therapeutics Inc. for the year ended December 31, 2014.
/s/ McGladrey LLP
Boston, Massachusetts
March 13, 2015